Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · SEI

Nicholas Partners Small Cap Growth Fund Retail Shares (NPSYX)

Ticker NPSYX · · Holdings as of Jun 30, 2026

Expense ratio
1.24%$124/yr per $10k
Net assets
$193.5Mall share classes
Holdings
96

Bottom line

Is NPSYX a good fund? The bottom line

NPSYX is the Retail share class of Nicholas Partners Small Cap Growth Fund, a managed small-cap mutual fund from SEI.

It charges 1.24% — about $124 a year on every $10,000 invested, more expensive than 74% of small-cap funds we track.

With $194 million in net assets and 96 holdings, its largest position is Revolution Medicines, Inc. (3.7%) and the top 10 make up 26.2% of the portfolio.

What to watch

  • Expensive for its category (1.24%)
  • 12b-1 marketing fee of 0.25% a year
  • High turnover (147% a year) can mean more taxable distributions

Updated Nov 19, 2026

What NPSYX invests in

The Nicholas Partners Small Cap Growth Fund (the Fund) seeks long-term capital appreciation.

Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in securities of small-capitalization companies. This investment policy may be changed by the Fund upon 60 days prior written notice to shareholders. The Fund considers small-capitalization companies to be those with market capitalizations within the range of the market capitalizations of companies in the Russell 2000 Growth Index at the time of purchase. While the market capitalization range of the Russell 2000 Growth Index changes throughout the year, as of September 30, 2025, the market capitalization range of the index was between approximately $9 million and $25.2 billion. The Fund primarily invests in common stocks, including initial public offerings (IPOs), but may also invest in convertible securities, real estate investment trusts (REITs), exchange-traded…

From the fund's prospectus (filed Feb 2, 2026).

What NPSYX costs

On a $10,000 investment, NPSYX's 1.24% expense ratio costs about $124 a year. The prospectus estimates $1,573 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full NPSYX fee table →

NPSYX top 10 holdings

#Holding% of fund
1Revolution Medicines, Inc.3.69%
2Bwx Technologies, Inc.3.45%
3N/a3.02%
4Callaway Golf Company2.83%
5Modine Manufacturing Company2.68%
6Carpenter Technology Corporation2.30%
7Sterling Infrastructure, Inc.2.25%
8TFI International Inc.2.06%
9Lincoln Educational Services Corporation2.02%
10Lattice Semiconductor Corporation1.94%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 26.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to NPSYX

More funds like NPSYX →

NPSYX FAQ

What is the expense ratio of NPSYX?
NPSYX's expense ratio is 1.24%, which works out to about $124 a year for every $10,000 invested. The prospectus estimates total costs of $1,573 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is NPSYX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.24%); 12b-1 marketing fee of 0.25% a year; high turnover (147% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does NPSYX hold?
NPSYX's largest holdings are Revolution Medicines, Inc. (3.7%), Bwx Technologies, Inc. (3.4%), N/a (3.0%), Callaway Golf Company (2.8%), Modine Manufacturing Company (2.7%). It holds 96 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages NPSYX?
NPSYX is offered by SEI through Advisors' Inner Circle Fund III.